Autoimmune Hepatitis Market

• The autoimmune hepatitis market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2025–2034). This growth in market revenue is primarily propelled by increasing diagnosis rates through advanced biomarker assays, the introduction of targeted immunomodulatory therapies with steroid‑sparing profiles, and favorable orphan‑drug incentives that spur investment and adoption.
• The increasing cases of autoimmune hepatitis may be attributed to improved diagnostic sensitivity from advanced serological and imaging tools, greater clinician awareness and adherence to screening guidelines, and a rise in environmental and medication‑related triggers in genetically susceptible individuals.
• No currently approved autoimmune hepatitis therapies retain patent exclusivity—long‑standing cornerstone drugs such as prednisone, azathioprine, and budesonide are off‑patent with multiple generics available, leaving a gap for novel branded agents. This generic saturation suppresses pricing power and reduces commercial incentive for incremental modifications of established treatments.
• The autoimmune hepatitis market remains in its infancy and dominated by low‑cost generics, with no exclusive branded therapies. Kezar Life Sciences’ immunoproteasome inhibitor, zetomipzomib, among others, represents a late‑stage proprietary candidate in Phase IIa trials. As zetomipzomib and similar mechanism‑focused agents gain approval, treatment paradigms will shift from broad‑spectrum corticosteroids, intensifying competition and accelerating market growth through 2034.
• In March 2025, Kezar Life Sciences announced positive topline results from the Phase IIa PORTOLA trial of zetomipzomib in autoimmune hepatitis. The drug demonstrated steroid-sparing biochemical remissions consistent with American Association for the Study of Liver Diseases (AASLD) guidelines in a refractory patient population. A favorable safety profile and durable responses were observed, with no disease flares reported in patients achieving remission.

DelveInsight’s comprehensive report titled “Autoimmune Hepatitis — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of autoimmune hepatitis. The report presents historical and projected epidemiological data covering total prevalent cases of autoimmune hepatitis, total diagnosed prevalent cases of autoimmune hepatitis, gender-specific diagnosed prevalent cases of autoimmune hepatitis, age-specific diagnosed prevalent cases of autoimmune hepatitis, type-specific diagnosed prevalent cases of autoimmune hepatitis, and treated cases of autoimmune hepatitis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in autoimmune hepatitis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Autoimmune Hepatitis Overview

Autoimmune hepatitis is a chronic condition in which the immune system mistakenly attacks the liver, leading to inflammation. If not properly managed, it can progress over time and result in cirrhosis or liver failure. The disease is long-lasting and requires ongoing medical attention to prevent serious complications.

There are two recognized types of autoimmune hepatitis. Type 1 is the more common form, affecting individuals of any age but seen more frequently in females. Type 2 is less common and typically presents in children, especially girls between the ages of 2 and 14. While the exact cause is unknown, the disease is believed to arise from a combination of genetic susceptibility, immune system dysfunction, and environmental triggers. Certain medications—including nitrofurantoin, minocycline, and hydralazine—as well as infections such as viral hepatitis, herpes simplex, and cytomegalovirus, have been associated with the onset of this condition.

Autoimmune Hepatitis Diagnosis and Treatment Algorithm 

Diagnosing autoimmune hepatitis typically starts with a detailed medical history and physical examination, followed by liver function tests, complete blood counts, coagulation studies, and other biochemical assessments. When initial findings are inconclusive, imaging techniques such as ultrasound and confirmatory procedures like liver biopsy are often used to establish a definitive diagnosis.

Management of autoimmune hepatitis centers on immune suppression to prevent ongoing liver damage. Standard therapies, including prednisone and azathioprine, have demonstrated strong efficacy in inducing remission and remain the cornerstone of treatment. In severe or treatment-resistant cases, liver transplantation may be necessary, underscoring the ongoing need for innovative therapies that can improve long-term outcomes and potentially reduce transplant dependency.

Autoimmune Hepatitis Epidemiology

The epidemiology section of the autoimmune hepatitis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of autoimmune hepatitis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to the secondary research, the prevalence of autoimmune hepatitis in the US is approximately 31.2 per 100,000 individuals.
• It was noted that autoimmune hepatitis prevalence was higher in females at 45.0 per 100,000 compared to 13.9 per 100,000 in males in the US.
• Based on age, autoimmune hepatitis prevalence peaked in the 7th decade of life and declined thereafter. Specifically, prevalence in the elderly (>65 years) was 59.0 per 100,000, compared to 28.5 per 100,000 in adults (18–65 years) and 2.4 per 100,000 in children (<18 years) in the US.
• European studies estimate the prevalence of autoimmune hepatitis at approximately 11–25 per 100,000. Type 2 autoimmune hepatitis is most commonly diagnosed in children and young adults, often presenting with fulminant hepatic failure.
• Of the two types of autoimmune hepatitis, 80% are classified as type 1. This type predominantly affects young or middle-aged females, accounting for 75% of cases.
• A European study found that autoimmune hepatitis can occur at any age, but it predominantly affects middle-aged women aged 40–60, with a male-to-female ratio of 1:4–1:6. Early epidemiological reports indicated onset peaks at ages 10–30 and 40–60.
• The prevalence of autoimmune hepatitis was observed to be nearly 23/100,000 inhabitants in Germany.
• The prevalence of autoimmune hepatitis was reported to be approximately 23.4/100,000 in Japan.
• In Japan, the male-to-female ratio for patients diagnosed with autoimmune hepatitis was found to be nearly 1:4, with a higher prevalence among females. Although many affected individuals were middle-aged women in their fifties and sixties, the disease was also found in young women and children.
• The epidemiology of autoimmune hepatitis is expected to change during the forecast period (2025-2034).

Autoimmune Hepatitis Market Outlook

The autoimmune hepatitis therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the autoimmune hepatitis market in the 7MM is expected to change significantly during the forecast period 2025–2034.

Autoimmune Hepatitis Drug Chapters 

Emerging Autoimmune Hepatitis Drugs

The autoimmune hepatitis market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as Zetomipzomib, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

Zetomipzomib (KZR-616): Kezar Life Sciences

Zetomipzomib (KZR-616) is a first-in-class selective immunoproteasome inhibitor that modulates critical immune system pathways by disrupting inflammatory cytokine production and immune cell activity, including macrophages, B cells, and T cells. Unlike conventional therapies that rely on broad immunosuppression or targeted immune signals, Zetomipzomib provides a more comprehensive regulation of immune dysfunction. This mechanism enables it to serve as a steroid-sparing agent, potentially reducing the adverse effects linked to long-term steroid use, and positions it as a promising therapeutic option for multiple autoimmune diseases with significant unmet needs.

Preclinical studies have shown that this targeted inhibition induces a broad anti-inflammatory effect in animal models without causing general immunosuppression. Phase I clinical trial data indicate that zetomipzomib has a favorable safety and tolerability profile, supporting its development for severe, chronic autoimmune conditions.

The partial clinical hold on zetomipzomib in lupus nephritis is being addressed by Kezar Life Sciences, which will respond promptly to all comments from the US FDA Division of Hepatology. Upon removal of the hold, the company intends to collaborate with both the US FDA and European Medicines Agency to plan a potential registrational study in autoimmune hepatitis.

In October 2024, Kezar Life Sciences announced that the Independent Data Monitoring Committee (IDMC) completed a safety review of the ongoing Phase IIa PORTOLA trial of zetomipzomib in autoimmune hepatitis, recommending that the study proceed without modification.

Autoimmune Hepatitis Market Segmentation

DelveInsight’s ‘Autoimmune Hepatitis – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future autoimmune hepatitis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Autoimmune Hepatitis Market Size by Countries

The autoimmune hepatitis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) autoimmune hepatitis market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Autoimmune Hepatitis Market Size by Therapies

Autoimmune Hepatitis Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034.

Autoimmune Hepatitis Drugs Uptake

This section focuses on the sales uptake of potential autoimmune hepatitis drugs that have recently been launched or are anticipated to be launched in the autoimmune hepatitis market between 2020 and 2034. It estimates the market penetration of autoimmune hepatitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the autoimmune hepatitis market.

The emerging autoimmune hepatitis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the autoimmune hepatitis market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on autoimmune hepatitis.

Autoimmune Hepatitis Market Access and Reimbursement

DelveInsight’s ‘Autoimmune Hepatitis – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of autoimmune hepatitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current autoimmune hepatitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the autoimmune hepatitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or autoimmune hepatitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the autoimmune hepatitis unmet needs.

Autoimmune Hepatitis: KOL Insights

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Massachusetts General Hospital, US, University of Mainz, Germany, University of Barcelona, Barcelona, Spain, ellvitge-Idibell University Hospital, Barcelona, Spain, University of Leeds, Leeds, UK, and Juntendo University School of Medicine, Japan, among others.

“Timely identification and treatment of autoimmune hepatitis are crucial for preventing liver damage and improving patient outcomes. Early use of corticosteroids and immunosuppressants can effectively manage inflammation and autoimmune activity.”

“Continuous monitoring and tailored therapy are essential for long-term management of autoimmune hepatitis. Adjusting treatment based on patient response and potential side effects helps maintain disease control and enhance quality of life.”

“Differentiating autoimmune hepatitis from other liver diseases, such as viral hepatitis or primary biliary cholangitis, requires comprehensive evaluation of patient history, clinical symptoms, and specific autoantibody profiles. This thorough diagnostic process ensures appropriate and targeted therapy.”

Note: Detailed assessment of KOL Views will be provided in the full report on Autoimmune Hepatitis.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the autoimmune hepatitis Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Autoimmune Hepatitis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for autoimmune hepatitis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging autoimmune hepatitis therapies.

Autoimmune Hepatitis Report Insights

• Autoimmune Hepatitis Patient Population
• Therapeutic Approaches
• Autoimmune Hepatitis Pipeline Analysis
• Autoimmune Hepatitis Market Size and Trends
• Autoimmune Hepatitis Market Opportunities
• Impact of Upcoming Therapies

Autoimmune Hepatitis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Autoimmune Hepatitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Autoimmune Hepatitis Market
• Autoimmune Hepatitis Drugs Uptake

Autoimmune Hepatitis Report Assessment

• Autoimmune Hepatitis Current Treatment Practices
• Unmet Needs
• Autoimmune Hepatitis Pipeline Product Profiles
• Autoimmune Hepatitis Market Attractiveness

Key Questions

• How common is autoimmune hepatitis?
• What are the key findings of autoimmune hepatitis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for autoimmune hepatitis?
• What are the disease risk, burden, and unmet needs of autoimmune hepatitis?
• At what CAGR is the autoimmune hepatitis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
• How would the unmet needs impact the autoimmune hepatitis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of autoimmune hepatitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
• How many companies are currently developing therapies for the treatment of autoimmune hepatitis?   

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the autoimmune hepatitis Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future. 
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.